Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 3, 2009, Pages 697-700

  Scott, David A ^a   Balliet, Carrie L ^a   Cook, Donald J ^a   Davies, Audrey M ^a   Gero, Thomas W ^a   Omer, Charles A ^a   Poondru, Srinivasu ^a   Theoclitou, Maria Elena ^a   Tyurin, Boris ^a   Zinda, Michael J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

CSF 1R; Kinase inhibitor; Quinoline

Indexed keywords

3 AMIDO 4 ANILINOQUINOLINE DERIVATIVE; AMIDE; ANILINE DERIVATIVE; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; EPHRIN A5; EPHRIN B4; GLYCOGEN SYNTHASE KINASE 3ALPHA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PHOSPHOTRANSFERASE; PROTEIN JNK3; PROTEIN MST1; PROTEIN MST2; PROTEIN TBK1; QUINOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINOLINES; RATS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 58849133676     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.12.046     Document Type: Article

References (28)

1. Pollard J.W. Nat. Rev. Cancer 4 (2004) 71
2. Lewis C.E., and Pollard J.W. Cancer Res. 66 (2006) 605
3. Kamb A., Wee S., and Lengauer C. Nat. Rev. Drug Disc. 6 (2007) 115
4. Force T., Krause D.S., and Van Etten R.A. Nat. Rev. Cancer 7 (2007) 332
5. Daub H., Specht K., and Ullrich A. Nat. Rev. Drug Disc. 3 (2004) 1001
6. Scott D.A., Aquila B.M., Bebernitz G.A., Cook D.J., Dakin L.A., Deegan T.L., Hattersley M.M., Ioannidis S., Lyne P.D., Omer C.A., Ye M., and Zheng X. Bioorg. Med. Chem. Lett. 18 (2008) 4794
7. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., and Richards L. Bioorg. Med. Chem. Lett. 11 (2001) 1911
8. Hennequin L.F., Stokes E.S.E., Thomas A.P., Johnstone C., Ple P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., and Curwen J.O. J. Med. Chem. 45 (2002) 1300
9. Boschelli D.H., Wang Y.D., Ye F., Wu B., Zhang N., Dutia M., Powell D.W., Wissner A., Arndt K., Weber J.M., and Boschelli F. J. Med. Chem. 44 (2001) 822
10. Smalley Jr. T.L., Chamberlain S.D., Mills W.Y., Musso D.L., Randhawa S.A., Ray J.A., Samano V., and Frick L. Bioorg. Med. Chem. Lett. 17 (2007) 6257
11. Myers M.R., Setzer N.N., Spada A.P., Persons P.E., Ly C.Q., Maguire M.P., Zulli A.L., Cheney D.L., Zilberstein A., Johnson S.E., Franks C.F., and Mitchell K.J. Bioorg. Med. Chem. Lett. 7 (1997) 421
12. Ohno H., Kubo K., Murooka H., Kobayashi Y., Nishitoba T., Shibuya M., Yoneda T., and Isoe T. Mol. Cancer Ther. 5 (2006) 2634
13. Conway J.G., McDonald B., Parham J., Keith B., Rusnak D.W., Shaw E., Jansen M., Lin P., Payne A., Crosby R.M., Johnson J.H., Frick L., Lin M.-H.J., Depee S., Tadepalli S., Votta B., James I., Fuller K., Chambers T.J., Kull F.C., Chamberlain S.D., and Hutchins J.T. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 16078
14. Irvine K.M., Burns C.J., Wilks A.F., Su S., Hume D.A., and Sweet M.J. FASEB J. 20 (2006) 1921
15. Patch R.J., Brandt B.M., Asgari D., Baindur N., Chadha N.K., Georgiadis T., Cheung W.S., Petrounia I.P., Donatelli R.R., Chaikin M.A., and Player M.R. Bioorg. Med. Chem. Lett. 17 (2007) 6070
16. Illig C.R., Chen J., Wall M.J., Wilson K.J., Ballentine S.K., Rudolph M.J., DesJarlais R.L., Chen Y., Schubert C., Petrounia I.P., Crysler C.S., Molloy C.J., Chaikin M.A., Manthey C.L., Player M.R., Tomczuk B.E., and Meegalla S.K. Bioorg. Med. Chem. Lett. 18 (2008) 1642
17. Wall M.J., Chen J., Meegalla S.K., Ballentine S.K., Wilson K.J., DesJarlais R.L., Schubert C., Chaikin M.A., Crysler C.S., Petrounia I.P., Donatelli R.R., Yurkow E.J., Boczon L., Mazzulla M., Player M.R., Patch R.J., Manthey C.L., Molloy C.J., Tomczuk B.E., and Illig C.R. Bioorg. Med. Chem. Lett. 18 (2008) 2097
18. Huang H., Hutta D.A., Hu H., DesJarlais R.L., Schubert C., Petrounia I.P., Chaikin M.A., Manthey C.L., and Player M.R. Bioorg. Med. Chem. Lett. 18 (2008) 2355
19. A description of the cell assay is contained in Ref. 5.
20. 50 determination of compound inhibition activity is monitored with 11 point, 3-fold dilution of compound as added to enzyme reaction. Compounds 24 and 45-54 were screened in the enzyme assay described in: Almeida, L.; Aquila, B.; Cook, D.; Cowen, S.; Dakin, L.; Ezhuthachan, J.; Ioannidis, S.; Lee, S.; Lyne, P.; Pontz, T.; Scott, D.; Su, M.; Zheng, X. WO 06067445 A2 20060629; Chem. Abstr., 145, 124467. The two assays gave comparable data when compounds were screened in both.
21. Burke T.R., Lim B., Marquez V.E., Li Z.-H., Bolen J.B., Stefanova I., and Horak I.D. J. Med. Chem. 36 (1993) 425
22. Solubility is equilibrium solubility in pH 7.4 phosphate buffer.
23. Wolfe J.P., Wagaw S., Marcoux J.-F., and Buchwald S.L. Acc. Chem. Res. 31 (1998) 805
24. Hartwig J.F. Angew. Chem. Int. Ed. 37 (1998) 2046
25. Jagdmann G.E., Munson H.R., and Gero T.W. Synth. Commun. 20 (1990) 1203
26. Liu Y.-Y., and Minich M. J. Labelled Compd. Radiopharm. 18 (1981) 791
27. ® 80.
28. KinaseProfiler Department, Millipore UK Limited, Gemini Crescent, Dundee Technology Park, Dundee DD2 1SW, UK.